Martin L Brown1, Gerald F Riley, Nicki Schussler, Ruth Etzioni. 1. Health Services and Economics Branch, Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland 20892-7344, USA. mb53o@nih.gov
Abstract
BACKGROUND: Cancer-specific medical care costs are used by health service researchers, medical decision analysts, and health care policymakers. The SEER-Medicare database is a unique data resource that makes it possible to derive incidence- and prevalence-based estimates of cancer-related medical care costs by site and stage of disease, by treatment approach, and for age and gender strata for individuals older than 65 years. OBJECTIVES: This paper describes the cost-related data available in the SEER-Medicare database, and discusses techniques and methods that have been used to derive various cost estimates from these data. The limitations of SEER-Medicare data as a source of cost estimates are also discussed. RESULTS: Examples of cost estimates for colorectal and breast cancer derived from SEER-Medicare are presented, including estimates of incidence-based cost (average cost per patient) by the initial, terminal, and continuing care phases of cancer treatment. Estimates of cancer-related treatment costs, costs by type of treatment, and long-term costs are presented, as are prevalence-based costs (aggregate Medicare and national expenditures) by cancer type.
BACKGROUND:Cancer-specific medical care costs are used by health service researchers, medical decision analysts, and health care policymakers. The SEER-Medicare database is a unique data resource that makes it possible to derive incidence- and prevalence-based estimates of cancer-related medical care costs by site and stage of disease, by treatment approach, and for age and gender strata for individuals older than 65 years. OBJECTIVES: This paper describes the cost-related data available in the SEER-Medicare database, and discusses techniques and methods that have been used to derive various cost estimates from these data. The limitations of SEER-Medicare data as a source of cost estimates are also discussed. RESULTS: Examples of cost estimates for colorectal and breast cancer derived from SEER-Medicare are presented, including estimates of incidence-based cost (average cost per patient) by the initial, terminal, and continuing care phases of cancer treatment. Estimates of cancer-related treatment costs, costs by type of treatment, and long-term costs are presented, as are prevalence-based costs (aggregate Medicare and national expenditures) by cancer type.
Authors: Benjamin Z Galper; Andrew Moran; Pamela G Coxson; Mark J Pletcher; Paul Heidenreich; Lawrence D Lazar; Nicolas Rodondi; Y Claire Wang; Lee Goldman Journal: Circulation Date: 2011-12-05 Impact factor: 29.690
Authors: Amresh D Hanchate; Kerri M Clough-Gorr; Arlene S Ash; Soe Soe Thwin; Rebecca A Silliman Journal: J Gen Intern Med Date: 2010-06-08 Impact factor: 5.128
Authors: Christopher R Flowers; Stacey A Fedewa; Amy Y Chen; Loretta J Nastoupil; Joseph Lipscomb; Otis W Brawley; Elizabeth M Ward Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-07-06 Impact factor: 4.254
Authors: Grace L Smith; Jinhai Huo; Sharon H Giordano; Kelly K Hunt; Thomas A Buchholz; Benjamin D Smith Journal: Int J Radiat Oncol Biol Phys Date: 2015-05-14 Impact factor: 7.038
Authors: Michaela A Dinan; Yanhong Li; Yinghong Zhang; Suzanne B Stewart; Lesley H Curtis; Daniel J George; Shelby D Reed Journal: Clin Genitourin Cancer Date: 2015-08-06 Impact factor: 2.872
Authors: Ashish A Deshmukh; Hui Zhao; Prajnan Das; Elizabeth Y Chiao; Yi-Qian Nancy You; Luisa Franzini; David R Lairson; Michael D Swartz; Sharon H Giordano; Scott B Cantor Journal: Am J Clin Oncol Date: 2018-07 Impact factor: 2.339
Authors: Sujha Subramanian; Florence K L Tangka; Susan A Sabatino; David Howard; Lisa C Richardson; Susan Haber; Michael T Halpern; Sonja Hoover Journal: Medicare Medicaid Res Rev Date: 2013-01-17